Mark Cotton, MD, PhD is Head of Division of Paediatric Infectious Diseases and Director of the Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at Tygerberg Children’s Hospital (TCH), Faculty of Health Sciences, Stellenbosch University. He completed a 3 year fellowship in pediatric infectious diseases at University of Colorado- Denver, and also conducted laboratory-based research on apoptosis in pediatric HIV under the supervision of Dr Terri Finkel at the National Jewish Center for Respiratory Diseases and Immunology. On return to Tygerberg Academic Hospital, he completed a PhD on the role of apoptosis in paediatric HIV infection. He has been conducting a number of multicenter trials focusing on TB and HIV in children. He is a member of WHO technical task teams on HIV staging, ART and guidelines for Tuberculosis in children since 2004. He is a Specialist in Pediatric Infectious Diseases with extensive experience in managing HIV-infected children. He has been co-PI and investigator in a number of randomized clinical trials in children, both studies ART strategy and isoniazid prophylaxis and also ARV pharmacokinetics in HIV-infected children. The majority of studies are funded through the International Maternal Pediatric Adolescent AIDS Clinical Trial Group (IMPAACT). He is also the director of the Children’s Infectious Diseases Clinical Research Unit (KID-CTU) (clinical trial unit).